IgG4相关性慢性硬化性脑膜炎1例

2019-02-01 阳吉虎 纪涛 郭见 中国临床神经外科杂志

男,53岁,因双下肢活动障碍4年、加重10 d入院。4年前,头颅MRI示双额颞硬膜下血肿(图1A、1B),MRV示矢状窦闭塞(图1C),保守治疗好转出院,之后反复出现癫痫发作,双下肢活动障碍。10 d 前,双下肢活动障碍加剧,不能站立。体格检查:双上肢肌力、肌张力正常,双下肢肌力3级,肌张力呈齿轮样强直,双侧Babinshi征(+),Kerning征(-)。

1. 病例资料
 
男,53岁,因双下肢活动障碍4年、加重10 d入院。4年前,头颅MRI示双额颞硬膜下血肿(图1A、1B),MRV示矢状窦闭塞(图1C),保守治疗好转出院,之后反复出现癫痫发作,双下肢活动障碍。10 d 前,双下肢活动障碍加剧,不能站立。体格检查:双上肢肌力、肌张力正常,双下肢肌力3级,肌张力呈齿轮样强直,双侧Babinshi征(+),Kerning征(-)。
 
复查CT:右侧额部、左侧额颞顶内板下见新月形高密度血肿,纵裂池及天幕见出血铸型(图1D)。行双侧冠状切口额颞硬膜下血肿清除术,骨窗大小6 cm×8 cm,见硬膜增厚,表面见肉芽样赘生物,质硬(图1E),最厚处达1.5 cm,未见血肿及血肿机化,锐性分离病变硬膜,硬膜内侧与脑组织粘连,见术区脑组织肿胀,皮层表面无静脉血管,鉴于脑膜病变广泛无法全部切除,且性质不明,终止手术,因脑组织肿胀去骨瓣减压。
 




图1 IgG4 相关性慢性硬化性脑膜炎影像及肉眼观察A. 术前MRI T2WI,双侧额部硬膜低信号,明显增厚;B. 术前MRI T2WI 矢状面,小脑幕、额部硬膜呈低信号,明显增厚,压迫脑实质(↑示);C. 术前MRV 示矢状窦闭塞;D. 术前CT 示小脑幕及右侧大脑半球明显高密度灶,似硬膜下血肿;E. 切除标本见硬膜肥厚,血运差,质地坚硬;
 
术后病理示IgG4相关性硬化性脑膜炎(图2)。术后出现失语,脑组织肿胀(图1F),顽固性低蛋白血症,尿蛋白阴性,给予以甲泼尼龙冲击治疗,1.0 g+50 ml生理盐水,微量泵入,维持24 h;5 d后缓慢减量至口服泼尼松片(10 mg/d)。随后出现肺部感染,全身水肿,意识障碍进行性加重,术后1个月死于重症肺炎、多脏器功能衰竭。
 

图1F. 术后CT示脑肿胀,周围大片水肿
 

图2 IgG4 相关性慢性硬化性脑膜炎病理表现(HE染色)A. 硬脑膜明显增厚,组织大部分区域胶原化伴玻璃样变,其内可见散在灶性增生的脑膜上皮(×100);B. 淋巴滤泡形成,局部见少量梭形细胞增生,呈束状或漩涡状排列(×200);C. 见多灶性淋巴细胞、浆细胞浸润(×200)
 
2. 讨论
 
IgG4相关性硬化性疾病是一种与自身免疫相关性、多系统相关性慢性疾病,伴或不伴血清IgG4升高,病因尚不明确,可能是抗原驱动T淋巴细胞和B淋巴细胞,活化CD4+细胞,使IgG4阳性浆细胞浸润,导致胶原蛋白沉积。该病可累及全身多个组织器官,最常累及胰腺,其次为泪腺、涎腺、肺、主动脉,受累器官因纤维化、慢性炎症而出现增生肥厚,从而导致相应的压迫、阻塞和功能障碍。IgG4相关性慢性硬化性脑膜炎是IgG4相关性疾病中的一种表现形式,可能与感染有关。
 
有报道指出外伤后慢性硬膜下血肿钻孔引流术可刺激硬脑膜或异物诱发硬脑膜感染,继而促发自身免疫反应,最终导致硬脑膜增厚,纤维组织增生。临床主要表现为硬脑膜肥厚导致的压迫和颅神经症状,头痛最常见,其次为颅神经受累症状。本文病例主要表现为双下肢活动障碍及癫痫发作,可能为增厚的硬脑膜压迫脑实质及矢状窦闭塞导致静脉回流障碍出现的脑神经功能障碍。本病诊断主要依靠CT、MRI等影像学检查及血清IgG、IgG4水平,病理组织活检是诊断该疾病的“金标准”。
 
CT及MRI主要变现为病变部位硬脑膜增厚,增强明显强化,静脉窦闭塞。2011年日本IgG4研究小组提出IgG4相关性疾病的诊断标准:一个或多个器官弥漫性/局灶性肿大;血清IgG4>1350 mg/L;显著的淋巴浆细胞浸润伴纤维化;组织浸润的IgG4+/IgG+浆细胞比值>40%,且每高倍视野下IgG4+浆细胞>10个。同时满足上述3个条件即可诊断IgG4相关性疾病。尽管目前对IgG4相关性慢性硬化性脑膜炎的认识日益加深,但尚缺乏统一的诊断、治疗标准。目前多数研究报道证明糖皮质激素对IgG4相关性慢性硬化性脑膜炎有较好的治疗效果,可减轻临床症状并使肥厚病变的硬脑膜缩小,但复发常见。

原始出处:

阳吉虎,纪涛,郭见,黎震,李维平,黄国栋.IgG4相关性慢性硬化性脑膜炎1例[J].中国临床神经外科杂志,2018(01):62-63.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837636, encodeId=7352183e63674, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Oct 29 00:53:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482970, encodeId=0a3e14829e03f, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496328, encodeId=b07314963287e, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8119265602, createdName=Smile2683, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615197, encodeId=32fa161519ebb, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837636, encodeId=7352183e63674, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Oct 29 00:53:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482970, encodeId=0a3e14829e03f, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496328, encodeId=b07314963287e, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8119265602, createdName=Smile2683, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615197, encodeId=32fa161519ebb, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837636, encodeId=7352183e63674, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Oct 29 00:53:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482970, encodeId=0a3e14829e03f, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496328, encodeId=b07314963287e, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8119265602, createdName=Smile2683, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615197, encodeId=32fa161519ebb, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837636, encodeId=7352183e63674, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Oct 29 00:53:00 CST 2019, time=2019-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482970, encodeId=0a3e14829e03f, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496328, encodeId=b07314963287e, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8119265602, createdName=Smile2683, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615197, encodeId=32fa161519ebb, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sun Feb 03 06:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]

相关资讯

“IgG4相关疾病”得到明确——它让一些“癌症病人”得到昭雪

医学无止境,不时会有一些非常疑难的疾病展现在医生面前。难到什么程度?“无名氏”疾病!医生没有办法下诊断,“喊”不出其名字,是因为这个疾病还没有被命名。

IgG4相关性疾病临床表现多样,谨防误诊

2018年5月11日,《关于公布第一批罕见病目录的通知》公布,IgG4相关性疾病名列其中。那么何为IgG4相关性疾病?IgG4相关性疾病相关性疾病为何逐渐得到了国际社会的关注和重视?

解读《IgG4相关性疾病管理和治疗的国际共识指南》

2015年3月,Arthritis&Rheumatology杂志发表了《IgG4相关性疾病管理和治疗的国际共识指南》,以下简称指南。该指南是迄今为止国际上关于IgG4相关性疾病(IgG4-relateddisease,IgG4-RD)诊治和管理的首个指导性意见,对指导IgG4-RD的临床实践有重要意义。 指南制定背景 IgG4-RD是一种免疫介导的炎症伴纤维化疾病,可影响多个器官,